Alkermes reports early proof-of-concept for orexin-2 drug in ADHD
Alkermes announced early-stage trial results for ALKS 7290, an orexin‑2 receptor agonist originally being developed for narcolepsy, showing proof of concept in ADHD.
The study reported dose‑dependent, clinically meaningful improvements on exploratory measures of symptom severity, which analysts called promising though not surprising.
A Phase 2 study is currently underway with results expected in 2027, positioning the candidate among several orexin‑targeting programs for ADHD.
The announcement arrived alongside other industry updates, such as AbbVie’s AI‑driven discovery initiatives and an FDA label expansion for Eli Lilly’s breast‑cancer medication, but the Alkermes data were the headline focus.
This writeup was produced by pharmadog from original reporting by BioPharma Dive.
Original headline: “An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide”
read at BioPharma Dive ↗
comments(0)
5-min edit window · permanent after that